Brief: Pharnext Says PXT3003 For Treatment Of Charcot-Marie-Tooth Disease Type 1A Granted PIM Designation

Pharnext SCA

18/03/2020 07:46

March 18 (Reuters) - PHARNEXT SA  PHARN.PA :
    * PHARNEXT ANNOUNCES PXT3003 FOR TREATMENT OF
CHARCOT-MARIE-TOOTH
DISEASE TYPE 1AHAS BEEN GRANTED PIM DESIGNATION BY UK MEDICINES
AND HEALTHCARE PRODUCTS REGULATORY AGENCY
    * PIM DESIGNATION IS EARLY INDICATION THAT MEDICINAL PRODUCT
IS
PROMISING CANDIDATE FOR EARLY ACCESS TO MEDICINES SCHEME (EAMS)
IN TREATMENT, DIAGNOSIS OR PREVENTION OF LIFE-THREATENING OR
SERIOUSLY DEBILITATING CONDITIONS WITH UNMET NEED
    * WE LOOK FORWARD TO CONTINUING OUR DISCUSSIONS WITH U.S.
AND
EUROPEAN REGULATORY AUTHORITIES TO ADVANCE THE CLINICAL
DEVELOPMENT - CEO

Source text for Eikon:  ID:nEQ7nnjQMa 
Further company coverage:  PHARN.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))